Valeo Expects Full Enoxaparin Biosimilar Coverage By Year End
Covered For Public Reimbursement In Seven Provinces And Territories
Executive Summary
Canadian firm Valeo Pharma revealed the extent of coverage for its Lovenox biosimilars, months after launching the low molecular weight heparin in-licensed from Shenzhen Techdow Pharmaceutical.
You may also be interested in...
Quebec Reveals Details Of Biosimilar Switching Policy
Quebec has revealed further details of its biosimilar switching policy which is expected to generate annual savings of CAD100m by 2022. The move has received support from Biosimilars Canada, as other Canadian provinces pursue similar initiatives.
Enoxaparin Biosimilar Makes It Six For Sandoz Canada
Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.
Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit
Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.